Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jul;41(4):859-68.
doi: 10.1093/schbul/sbv022. Epub 2015 Mar 23.

The Impact of Aerobic Exercise on Brain-Derived Neurotrophic Factor and Neurocognition in Individuals With Schizophrenia: A Single-Blind, Randomized Clinical Trial

Affiliations
Randomized Controlled Trial

The Impact of Aerobic Exercise on Brain-Derived Neurotrophic Factor and Neurocognition in Individuals With Schizophrenia: A Single-Blind, Randomized Clinical Trial

David Kimhy et al. Schizophr Bull. 2015 Jul.

Abstract

Individuals with schizophrenia display substantial neurocognitive deficits for which available treatments offer only limited benefits. Yet, findings from studies of animals, clinical and nonclinical populations have linked neurocognitive improvements to increases in aerobic fitness (AF) via aerobic exercise training (AE). Such improvements have been attributed to up-regulation of brain-derived neurotrophic factor (BDNF). However, the impact of AE on neurocognition, and the putative role of BDNF, have not been investigated in schizophrenia. Employing a proof-of-concept, single-blind, randomized clinical trial design, 33 individuals with schizophrenia were randomized to receive standard psychiatric treatment (n = 17; "treatment as usual"; TAU) or attend a 12-week AE program (n = 16) utilizing active-play video games (Xbox 360 Kinect) and traditional AE equipment. Participants completed assessments of AF (indexed by VO2 peak ml/kg/min), neurocognition (MATRICS Consensus Cognitive Battery), and serum-BDNF before and after and 12-week period. Twenty-six participants (79%) completed the study. At follow-up, the AE participants improved their AF by 18.0% vs a -0.5% decline in the TAU group (P = .002) and improved their neurocognition by 15.1% vs -2.0% decline in the TAU group (P = .031). Hierarchical multiple regression analyses indicated that enhancement in AF and increases in BDNF predicted 25.4% and 14.6% of the neurocognitive improvement variance, respectively. The results indicate AE is effective in enhancing neurocognitive functioning in people with schizophrenia and provide preliminary support for the impact of AE-related BDNF up-regulation on neurocognition in this population. Poor AF represents a modifiable risk factor for neurocognitive dysfunction in schizophrenia for which AE training offer a safe, nonstigmatizing, and side-effect-free intervention.

Keywords: aerobic fitness; brain-derived neurotrophic factor/active-play video games; cognition; neurotrophins.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Comparison of changes in aerobic fitness and neurocognitive functioning following aerobic exercise training or treatment as usual. n = 26 (TAU = 13, AE = 13); Changes in aerobic fitness are indexed by VO2 peak (ml/kg/min); Changes in neurocognition are indexed by MATRICS Consensus Cognitive Battery composite T-scores.
Fig. 2.
Fig. 2.
Distribution of changes in neurocognitive functioning following aerobic exercise training or treatment as usual. n = 26 (TAU = 13, AE = 13); Neurocognitive Functioning—MATRICS Consensus Cognitive Battery composite T-score.
Fig. 3.
Fig. 3.
Association of changes in aerobic fitness, serum BDNF, and neurocognition. n = 26 (AE = 13, TAU = 13). (A) Association of changes in aerobic fitness and changes in neurocognition. (B) Association of changes in serum-BDNF and changes in neurocognition.

References

    1. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41–51. - PubMed
    1. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72:29–39. - PubMed
    1. Barch DM, Keefe RS. Anticipating DSM-V: opportunities and challenges for cognition and psychosis. Schizophr Bull. 2010;36:43–47. - PMC - PubMed
    1. Lewandowski KE, Cohen BM, Keshavan MS, Sperry SH, Ongür D. Neuropsychological functioning predicts community outcomes in affective and non-affective psychoses: a 6-month follow-up. Schizophr Res. 2013;148:34–37. - PMC - PubMed
    1. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64:633–647. - PubMed

Publication types

Substances